| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Department of Internal Medicine, Section of Hematology/Oncology, Medical University of Lübeck, Ratzeburger Allee 160, D-23538 Lübeck, Germany
The initial metabolism of ifosfamide (IFO) consists of two different pathways, which lead to the alkylating metabolite 4-hydroxy-IFO and to chloroacetaldehyde (CAA). CAA has been reported to cause side effects, such as neuro- and nephrotoxicity, whereas no direct antitumor effect has been described thus far. Therefore, two human tumor cell lines (MX1 and S117) and a renal tubular cell line (Landa Leiden) were exposed to 4-hydroxy-IFO, CAA, and a combination of both. The concentrations used were in the same range as measured in the blood of 10 patients treated with 5 g/m2 IFO. The cell survival was measured using the MTT assay. Similar dose-response curves were found for both metabolites. For the MX1 tumor, the IC50s of 4-hydroxy-IFO and CAA were 10.8 and 8.6 µM, respectively. For the reduction of S117 cell survival, higher concentrations of the metabolites were needed (25.0 µM 4-hydroxy-IFO and 15.3 µM CAA). Combination treatment of the cells resulted in an approximately additive effect. Both metabolites exhibited similar toxicity against Landa Leiden cells. Our results indicate that CAA has its own cytotoxic profile against tumor cells. Hence, we conclude that the molecular mechanism of action of IFO seems to be only in part an alkylating effect and that CAA may play an important role in the therapeutic efficacy of IFO.
1 To whom requests for reprints should be addressed.
Received 12/23/96. Accepted 5/ 5/97.
This article has been cited by other articles:
|
|
 |
|
  S. K. Bruggemann, S. Pfaffle, S. O. Peters, and T. Wagner Influence of Short-Term Use of Dexamethasone on the Pharmacokinetics of Ifosfamide in Patients Drug Metab. Dispos., October 1, 2007; 35(10): 1721 - 1724. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. DUBOURG, C. MICHOUDET, P. COCHAT, and G. BAVEREL Human Kidney Tubules Detoxify Chloroacetaldehyde, a Presumed Nephrotoxic Metabolite of Ifosfamide J. Am. Soc. Nephrol., August 1, 2001; 12(8): 1615 - 1623. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Briasoulis, I. Judson, N. Pavlidis, P. Beale, J. Wanders, Y. Groot, G. Veerman, M. Schuessler, G. Niebch, K. Siamopoulos, et al. Phase I Trial of 6-Hour Infusion of Glufosfamide, a New Alkylating Agent With Potentially Enhanced Selectivity for Tumors That Overexpress Transmembrane Glucose Transporters: A Study of the European Organization for Research and Treatment of Cancer Early Clinical Studies Group J. Clin. Oncol., October 20, 2000; 18(20): 3535 - 3544. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Börner, J. Kisro, S. K. Brüggemann, W. Hagenah, S. O. Peters, and T. Wagner Metabolism of Ifosfamide to Chloroacetaldehyde Contributes to Antitumor Activity In Vivo Drug Metab. Dispos., May 1, 2000; 28(5): 573 - 576. [Abstract] [Full Text]
|
|
|
|
 |
|
 S.V. Torti, F.M. Torti, S.P. Whitman, M.W. Brechbiel, G. Park, and R.P. Planalp Tumor Cell Cytotoxicity of a Novel Metal Chelator Blood, August 15, 1998; 92(4): 1384 - 1389. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
